EUROAPI Board Composition Change Announced
EUROAPI recently confirmed a pivotal shift in its board structure, reinforcing its adherence to strong governance practices. In a recent announcement, the company revealed that Rodolfo J. Savitzky, who has been serving as an Independent Director and Chair of the Audit Committee, will resign from his position effective December 31, 2025. This change comes right after his appointment as Chief Financial Officer at Recipharm, set to take effect on October 1, 2025.
Appointment of a New Independent Director
The search for a successor to Savitzky has already commenced, and EUROAPI anticipates that a new Independent Director will be appointed before the end of the year. This transition reflects the firm’s commitment to exceptional leadership and the continuous evolution of its board, aiming to drive the company's mission forward.
Chairman's Statement
Emmanuel Blin, the Chairman of EUROAPI, expressed heartfelt gratitude towards Rodolfo, acknowledging the instrumental role his expertise in the Contract Development and Manufacturing Organization (CDMO) industry has played during his tenure over the past three years. The Board and the management greatly valued his contributions, which have significantly impacted the organization’s governance.
Rodolfo Savitzky's Reflections
In his farewell remarks, Savitzky articulated his pride in serving EUROAPI and emphasized his commitment to the company's future. He stated, "It has been an honor to serve as EUROAPI’s Director and Chair of the Audit Committee and to contribute to its transformation journey." He expressed full confidence in the implementation of the Focus-27 plan and EUROAPI's position as a leader within the Active Pharmaceutical Ingredients (API) sector.
Upcoming Financial Events
EUROAPI provides its stakeholders with an outline of important upcoming financial dates, although specific timings are yet to be confirmed:
- 3 March: FY 2025 Results
- 27 May: 2026 Annual General Meeting
- 28 July: H1 2026 Results
About EUROAPI
EUROAPI is at the forefront of active ingredient solutions designed to sustainably fulfill the needs of customers and patients globally. As a leader in the active pharmaceutical ingredient arena, the company boasts a diverse portfolio of approximately 200 products. It focuses on offering a wide range of technologies while also pioneering the development of innovative molecules through its CDMO activities.
The enterprise prides itself on its commitment to enhancing health by facilitating access to essential therapies, a mission that resonates deeply with its over 3,270 employees. Supported by robust research and development capabilities, EUROAPI operates five manufacturing sites located across Europe, ensuring high-quality API production for clientele in more than 80 countries. As a publicly traded company, EUROAPI is listed on Euronext Paris with the ticker symbol EAPI.
Contact Information
Media Relations:
Laurence Bollack
Phone: +33 (0)6 81 86 80 19
Email: mr@euroapi.com
Investor Relations:
Sophie Palliez-Capian
Phone: +33 (0)6 87 89 33 51
Email: Sophie.palliez@euroapi.com
Léa Massonneau
Phone: +33 (0)7 60 32 29 50
Email: lea.massonneau@euroapi.com
Frequently Asked Questions
What recent changes have been announced for EUROAPI's board?
EUROAPI announced that Rodolfo J. Savitzky will resign from his role as Independent Director and Chair of the Audit Committee, effective December 31.
Why is Rodolfo J. Savitzky stepping down?
Rodolfo is stepping down to take on the role of Chief Financial Officer at Recipharm, effective October 1.
Who is leading the search for the new Independent Director?
The search for Rodolfo J. Savitzky’s successor has already begun, and EUROAPI expects to appoint a new Independent Director soon.
What did the Chairman say about Rodolfo's contributions?
Emmanuel Blin expressed sincere gratitude for Rodolfo's valuable input during his tenure, highlighting his experience in the CDMO industry as instrumental.
What are the upcoming financial agenda dates for EUROAPI?
The confirmed financial agenda includes results announcements scheduled for 3 March, 27 May for the AGM, and 28 July for H1 2026 results.
